Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Calcipotriene Foam · 1 trial · 1 indication
The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.
The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.
| Arm | Type | Description |
|---|---|---|
| Calcipotriene Foam | EXPERIMENTAL | Calcipotriene Foam 0.005%, |
| Vehicle Foam | PLACEBO_COMPARATOR | Vehicle Foam |
| Name | Type | Description |
|---|---|---|
| Calcipotriene Foam | DRUG | Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group |
| Vehicle Foam | DRUG | Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group |
Inclusion Criteria: * Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed. * Male or female subjects at least 12 years old and in good general...
Calcipotriene Foam is used for the treatment of psoriasis, a skin condition. It is being studied for use in patients with scalp and body psoriasis. The foam is a small molecule therapy being developed by GSK plc for dermatological use.
Calcipotriene Foam is a small molecule therapy. The specific molecular target of Calcipotriene Foam is not disclosed in the available information. It is being investigated for the treatment of psoriasis, a condition affecting the skin.
Calcipotriene Foam is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and effectiveness of this treatment for psoriasis.
Calcipotriene Foam is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being studied for the treatment of psoriasis.
Calcipotriene Foam has one completed Phase 3 clinical trial, identified as NCT01139580. This study evaluated the safety and effectiveness of Calcipotriene Foam in subjects with scalp and body psoriasis. The trial enrolled 363 participants in the United States and was randomized, double-blind, and placebo-controlled.
Calcipotriene Foam is a formulation of calcipotriene, a vitamin D analog used to treat psoriasis. The foam is a specific delivery form of this active ingredient, designed for application to the scalp and body. It is being developed by GSK plc for the treatment of psoriasis.